

Thanh Bach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2961161/publications.pdf>

Version: 2024-02-01

12
papers

116
citations

1306789

7
h-index

1372195

10
g-index

12
all docs

12
docs citations

12
times ranked

146
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0143221.	1.4	0
2	Development and validation of a simple and sensitive LC-MS/MS method for the quantification of cefazolin in human plasma and its application to a clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 210, 114521.	1.4	7
3	Importance of Utilizing Natural Isotopologue Transitions in Expanding the Linear Dynamic Range of LC-MS/MS Assay for Small-Molecule Pharmacokinetic Sample Analysis – A Mini-review. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 1245-1249.	1.6	3
4	Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	5
5	Comparing the performance of first-order conditional estimation (FOCE) and different expectation–maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite pharmacokinetic model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 581-595.	0.8	0
6	Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	17
7	Aspects of matrix and analyte effects in clinical pharmacokinetic sample analyses using LC-ESI/MS/MS – Two case examples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 183, 113135.	1.4	7
8	Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 171, 111-117.	1.4	14
9	Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	29
10	General Pharmacokinetic Features of Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Simulation-Based Study. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 394-405.	1.0	9
11	Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	14
12	Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	11